Divi's Laboratories Ltd

Stage 2 · Advancing · week 21Setup 7.0 ★★ GoodStrong +6.5

As of 9 Oct 2026, Divi's Laboratories is in Stage 2 — advancing, the uptrend phase, in week 21 (since 19 May 2026). It closed at ₹9,340, 3.0% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. More about the company

₹9,340
-0.22% today
₹2.48L Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dLabs & Life Sciences Services 33.3%0.0 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

7.0 ★★ Good

Momentum

Steady

Edge

Strong +6.5

Setup-score rank among Stage 2 peers: #1 of 2 in Labs & Life Sciences Services · #10 of 78 in Health Care

Is DIVISLAB early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-3.0%
₹5,817.5 lo₹9,624 hi
3.0% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 21
1w13w26w
Week 21 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
31.3%
200 DMA: ₹7,115.2 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.73x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +0.7% vs MA50 +11.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-2.5%
3M
+36.6%
6M
+58.8%
YTD
+44.2%
1Y
+63.6%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #15 of 74 Stage 2 stocks in Health Care by RS.
Industry
Labs & Life Sciences Services
→ Flat
Stage 2%
33.3%
20d Δ
+0.0pp
1M return
-3.0%
3M return
+32.5%
Industry Stage-2 % · last 20 days
Ranks #1 of 2 Stage 2 stocks in this industry. Top stock in industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 15w
S2 37w
S3 14w
S2 14w
S2 21w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 9w → S2 9w → S3 3w → S4 5w → S1 2w → S2 37w → S3 14w → S2 14w → S3 7w → S4 2w → S3 1w → S2 11w → S3 2w → S4 13w → S1 2w → S2 21w current
Total tracked: 168 weeks across 17 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-05-19
4 appearances in last 60 days. First seen: 2024-05-16.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 21 · Vol 0.73x
2026-10-08S2
Wk 21 · Vol 0.85x
2026-10-07S2
Wk 20 · Vol 0.81x
2026-10-06S2
Wk 20 · Vol 0.89x
2026-10-05S2
Wk 20 · Vol 0.93x
2026-10-01S2
Wk 20 · Vol 1.11x
2026-09-30S2
Wk 20 · Vol 1.07x
2026-09-29S2
Wk 19 · Vol 1.30x
2026-09-28S2
Wk 19 · Vol 0.76x
2026-09-25S2
Wk 19 · Vol 0.77x
2026-09-24S2
Wk 19 · Vol 1.31x
2026-09-23S2
Wk 19 · Vol 0.94x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
SHILPAMED
wk 22 · -4.8% from hi
7.6
Moving averages & range
50 DMA
₹9,005.1
200 DMA
₹7,115.2
52W High
₹9,624
52W Low
₹5,817.5
5D Low
₹9,196
Resistance levels (recent highs)
20d High
₹9,624
60d High
₹9,624
120d High
₹9,624
250d High
₹9,624
Next resistance
+3.0%
to 20d High
Ask the Market AI about DIVISLABAsk →
P/E (TTM)
70.4
Forward 48.1
Earnings Growth (YoY)
+13.6%
Revenue +9.5%
ROE
+16.2%
Profit margin +24.3%
Dividend Yield
0.44%
P/B 11.7
About this companyHealth Care· Labs & Life Sciences Services

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.